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In Parkinson’s disease, the efﬁcacy of L-Dopa treatment changes over time, as dyskinesias
emerge with previously beneﬁcial doses. Using MitoPark mice, that models mitochondrialAvailable online 16 June 2015
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failure in dopamine (DA) neurons and mimics the progressive loss of dopamine observed in
Parkinson’s disease, we found that the severity of DA denervation and associated adaptations
in striatal neurotransmission at the time of initiation of L-Dopa treatment determines
development of L-Dopa induced dyskinesias. We treated 20-week, and 28-week old MitoPark
mice with L-Dopa (10 mg/kg i.p. twice a day) and found locomotor responses to be signiﬁcantly
different. While all MitoPark mice developed sensitization to L-Dopa treatment over time, 28-
week old MitoPark mice with extensive striatal DA denervation developed abnormal involun-
tary movements rapidly and severely after starting L-Dopa treatment, as compared to a more
gradual escalation of movements in 20-week old animals that started treatment at earlier
stages of degeneration. Our data support that it is the extent of loss of DA innervation that
determines how soon motor complications develop with L-Dopa treatment. Gene array studies
of striatal neurotransmitter receptors revealed changes in mRNA expression levels for DA,
serotonin, glutamate and GABA receptors in striatum of 28-week old MitoParkmice. Our results
support that delaying L-Dopa treatment until Parkinson’s disease symptoms become more
severe does not delay the development of L-Dopa-induced dyskinesias. MitoPark mice model
genetic alterations known to impair mitochondrial function in a subgroup of Parkinson
patients and provide a platform in which to study treatments to minimize the development
of dyskinesia.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).5
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Development of treatment-induced motor complications consti-
tutes a major problem in the long-term management of patients
suffering from Parkinson’s disease. Particularly, L-Dopa-induced
dyskinesias (LIDs), also known as abnormal involuntary move-
ments, pose a signiﬁcant challenge. Most Parkinson’s disease
patients develop dyskinesia within a decade from onset of
treatment (Tambasco et al., 2012). Despite the clinical importance
of this side effect, the mechanisms underlying the generation of
LIDs are not fully understood, although there are data to suggest
it is the degree of dopamine loss, and the dose of L-Dopa, rather
than the length of L-Dopa treatment, that correlates to the
development and severity of dyskinesia (Cilia et al., 2014). Animal
models using selective neurotoxins to unilaterally mimic the
selective loss of substantia nigra neurons typical of Parkinson’s
disease, and have been used to assess LIDs (Lundblad et al., 2004;
Francardo et al., 2011; Winkler et al., 2002) and the efﬁcacy of
standard and novel therapeutic treatments. Several models based
on genes implicated in the pathogenesis of familial Parkinson’s
disease (e.g., α-synuclein and parkin) have been developed over
the last decade (Le et al., 2014). Although these animal models
display important characteristics of Parkinson’s disease, including
dystrophic neurites, neuronal atrophy, and intracellular inclu-
sions, degeneration of the nigrostriatal DA system has been
variable (Le et al., 2014). There is thus a need for additional
genetic models of Parkinson’s disease that carry hallmark fea-
tures in the basal ganglia, such as slow progressive, robust
bilateral degeneration of the nigrostriatal DA system, accompa-
nied by a gradual motor impairment, responsiveness to Parkin-
son’s disease medications (e.g., DA agonists and L-Dopa), and
associated development of dyskinesias.
MitoPark mice mimic the progression of Parkinson’s dis-
ease in humans, with adult onset and slowly progressing
neurological symptoms (Ekstrand et al., 2007). The MitoPark
mouse has a homozygous disruption of mitochondrial tran-
scription factor A (TFAM) selectively in midbrain DA neurons,
leading to mitochondrial dysfunction and gradual degenera-
tion of DA neurons. While the MitoPark mouse may not be
directly suitable to study the etiology of Parkinson’s disease,
as there are almost no indications of TFAM polymorphisms
being linked to Parkinson’s disease, the MitoPark mouse does
model mitochondrial failure, strongly implicated as one
common genetic denominator in Parkinson’s disease pathol-
ogy (Ekstrand et al., 2007; Galter et al., 2010). The MitoPark
phenotype results in uniform and progressive loss of DA
afferents in areas of the basal ganglia, starting in early
adulthood, in which nigrostriatal dopaminergic projections
innervating the dorsal striatum are strongly affected, while
mesolimbic dopaminergic projections innervating the ventral
striatum are relatively spared (Ekstrand et al., 2007; Galter
et al., 2010). This pattern of progressive DA neuron loss
recapitulates the gradual degeneration of DA projections
and associated motor symptoms typical of Parkinson’s dis-
ease in humans. The slow bilateral time course of nig-
rostriatal degeneration in MitoPark animals, over weeks to
months, compared with the days to weeks time of neurode-
generation in most toxin models also allows study of the
major risk factor for idiopathic Parkinson’s disease—age. Ourgenetic model also provides greater uniformity of animals
with respect to degree of DA degeneration, compared to toxin
models. Additionally, MitoPark mice are responsive to L-Dopa
therapy with a differential response depending on disease
stage (Galter et al., 2010; Gellhaar et al., 2015). Here we show
behavioral evidence of striatal neuroplasticity in response to
denervation of dopaminergic afferents, as well as in response
to chronic L-Dopa treatment. As severity of Parkinson’s
disease has been recognized as a risk factor for LIDs in
humans (Schrag et al. 2003; Schrag and Quinn, 2000; Kostic
et al., 1991; Kumar et al., 2005), we used the mouse model to
test whether involuntary movements in response to chronic
L-Dopa treatment was dependent on length of treatment, or
degree of degeneration. Our results suggest that the MitoPark
mouse may provide a preclinical model to study circuit-
related questions, and to probe therapeutic treatments in
relation to the formation of LIDs. Our results support the
current view that delaying the onset of L-Dopa treatment
does not delay development of LIDs.
A recent paper (Gellhaar, et al., 2015) came to similar
conclusions about the relationship of development of hyper-
activity and dyskinesia to the age of MitoPark mice and
therefore degree of DA loss, rather than duration of L-Dopa
treatment. There are some differences between this paper
and the current study. The MitoPark mice used here had an
internal ribosome entry sequence to drive cre recombinase
from the 30 untranslated region of the endogenous DAT gene,
minimizing any effects on DAT mRNA formation. In addition,
we used measurement of DA and metabolites by HPLC, rather
than tyrosine hydroxylase immunocytochemistry, to docu-
ment the age related DA loss. Finally, we also used
array analysis to investigate striatal mRNA encoding
relevant neurotransmittor receptors to monitor changes
which accompany the dyskinetic/hyperactivity behavior in
these mice.2. Results
2.1. Assessment of DA depletion in the striatum of
MitoPark mice
Neurochemical studies in dorsal striatum from MitoPark and
WT mice at 20- and 28 weeks of age points conﬁrmed here
the progressive DA neuron loss previously observed in sub-
stantia nigra and the striatal DA depletion in MitoPark mice
(Ekstrand et al., 2007; Ekstrand and Galter, 2009), and showed
signiﬁcant loss of DA and DOPAC in the dorsal striatum
compared to WT animals (Fig. 1). Previous studies have
shown a progressive loss of striatal dopamine in MitoPark
mice starting at 12 weeks of age, and continuing until 40
weeks of age (Ekstrand et al., 2007; Ekstrand and Galter, 2009).
In this study, a further signiﬁcant decline in DOPAC levels
was observed in 28-week old MitoPark mice, compared to 20-
week old MitoPark mice. DA levels were also signiﬁcantly
decreased in 28-week old, compared to 20-week old, MitoPark
mice (Fig. 1). This gradual degeneration over time is also
characteristic of Parkinson’s disease in humans.
Dopamine turnover, as HVAþDOPAC/DA, was measured in
MitoPark mice vs wild type at both 20 and 28 weeks of age.
Fig. 1 – Concentrations of DA (A) and DOPAC (B) levels in
striatum of control and MitoPark mice at 20 and 28 weeks of
age. Bars represent mean dopamine (A) and DOPAC (B) levels
from 5 animals per group and error bars indicate SEM. DA
and DOPAC levels were signiﬁcantly lower in both 20 and 28
week MitoPark mice compared to control animals. A
signiﬁcant DA reduction was observed as well in 28 week
old MitoPark mice as compared to 20-week old MitoPark
mice. (nnnpo0.001 ANOVA followed by Fisher’s protected
least signiﬁcant difference, PLSD). DOPAC levels were
signiﬁcantly reduced in 28-week old MitoPark mice, as
compared to 20-week old MitoPark mice ((B) nnnpo0.001,
ANOVA followed by Fisher’s protected least signiﬁcant
difference, PLSD).
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week wt, 0.88370.08 for 20 week MitoPark and 0.70670.09 for
28 week old MitoPark. Turnover rates between wt and
MitoPark were signiﬁcantly different (po0.001, ANOVA).2.2. L-Dopa induced locomotor behavior
Oral intake of the DA precursor L-Dopa elicits therapeutic
relief in Parkinson’s disease patients by restoring extracellu-
lar DA levels within the dorsal striatum. However, unlike
physiological DA transmission, this therapeutic regimen is
thought to lead to abnormal peaks of non-synaptic DA, which
over time trigger behavioral sensitization, eventually mani-
fested as abnormal involuntary movements (Iravani et al.,
2012). In this study we followed the pattern of horizontal
locomotor activity in MitoPark mice and age-matched con-
trols through chronic L-Dopa treatment. There was little
overall movement and no LIDs in 20 week old MitoPark mice
prior to L-Dopa administration. MitoPark mice in both age
groups (20- and 28-week old) developed sensitization to
L-Dopa treatment (Figs. 2 and 3). Interestingly, the initial andsubsequent response to L-Dopa differed between the two age
groups. Twenty eight week old parkinsonian mice showed an
increased sensitivity to initial L-Dopa administration (Fig. 3), as
the latency to reach L-Dopa peak activity decreased in this age
group, and total duration of the response to L-Dopa increased
when compared to 20-week old MitoPark mice (Fig. 2). This
trend continued throughout treatment, suggesting that the
continuous degeneration of DA terminals plays an important
role in modeling adaptations in the brain that ultimately result
in very different behavioral responses depending on the stage
of the disease at initiation of L-Dopa treatment.
2.3. Abnormal Involuntary movements
Development of L-Dopa induced dyskinesias correlated well with
locomotor activity data. Twenty-week old MitoPark mice showed
a very low incidence of LIDs at the initial stages of L-Dopa
treatment (Fig. 4), and did not develop more severe degrees of
LIDs until after 4–5 weeks of chronic L-Dopa treatment (Fig. 4).
Thus LIDs in 20-week old MitoPark mice developed progressively
with L-Dopa treatment. In contrast, 28-week MitoPark mice
manifested severe LIDs immediately after the ﬁrst L-Dopa injec-
tion (Fig. 4). The development of LIDs in 28-week old MitoPark
mice was thus abrupt and marked even after the 1st L-Dopa
injection. Control animals treated with L-Dopa did not develop
LIDs and therefore are not represented in Fig. 4. These data
suggest that the extent of loss of DA innervation and subsequent
adaptations in the striatum may determine how rapidly motor
complications develop after initiation of L-Dopa treatment.
2.4. Striatal neurotransmitter receptor mRNA expression
in 28-week old Mitopark mice
Behavioral results from 20- and 28-week old MitoPark mice
treated with L-Dopa, shown above, suggest that changes in
the basal ganglia as a result of the progressive loss of DA
neurons may be related to susceptibility to L-Dopa induced
dyskinesias in MitoPark mice. As 28-week old MitoPark mice
developed severe LIDs after acute treatment with L-Dopa,
real-time quantitative PCR analyses were performed in stria-
tal tissue to determine mRNA expression levels for various
neurotransmitter receptor families, as compared to aged-
matched WT controls. Progressive dopamine neuron degen-
eration resulted in signiﬁcant alterations in the expression of
mRNA species encoding neurotransmitter receptors in stria-
tum in 28-week old naïve MitoPark mice, as compared to
controls. Such alterations included dopaminergic, glutama-
tergic, gabaergic, cholinergic and serotonergic neurotransmit-
ter receptors (Table 1). As 28-week Mitopark mice are
particularly susceptible to developing L-Dopa induced dyski-
nesias, dysregulation of these neurotransmitter systems may
contribute to the increased susceptibility to LIDs.3. Discussion
A prerequisite for the development of L-Dopa induced dyski-
nesias appears to be the loss of dopamine nerve cells in
substantia nigra and of DA nerve terminals in striatum. The
rapid emergence of dyskinesia in Parkinson’s disease patients
Fig. 2 – Acute (A) and chronic (B–F) L-Dopa induced locomotor behavior in 20-week old MitoPark (dark bars) and control (white
bars) mice. Horizontal locomotor activity is plotted in 10 min increments. L-Dopa injections were given after 60 min of baseline
recordings, and recorded for 2 additional hours (grey box). MitoPark and control mice received the initial L-Dopa injection at 20
weeks of age (A), and continued to receive daily L-Dopa injections until 30-weeks of age (B–F). Control mice did not develop
sensitization to L-Dopa treatment (white bars). 20-week old MitoPark mice developed a progressive sensitization to L-Dopa
treatment with chronic treatment. After 10 weeks of L-Dopa treatment ((F) 30 weeks old), MitoPark mice showed a faster onset
and a longer response to L-Dopa injections, when compared to the same MitoPark cohort after the ﬁrst weeks of treatment.
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extensive at diagnosis, and the absence of dyskinesia in
normal humans chronically treated with L-Dopa (i.e., mis-
taken diagnosis) support this conjecture (Jankovic et al., 2000;
Kumar et al., 2005; Schrag and Quinn, 2000). Chronic stimula-
tion of the denervated striatum via the dopamine precursor,
L-Dopa, induces a process of sensitization that modiﬁes the
response to subsequent dopaminergic treatments (Nadjar
et al., 2009). This process, called priming, is associated with
changes in receptors for DA and other neurotransmitters and
may play a role in the development of neuronal maladapta-
tions and motor complications in humans. As data from
Parkinson’s disease patients suggest a close relationship
between priming, the development of LIDs in response to
treatment, and the level of DA loss in striatum (Nadjar et al.,
2009), it is of importance to develop a preclinical animal
model that recapitulates this aspect of the disease. Using a
parkinsonian mouse model, the MitoPark mouse, we show
that the interaction of L-Dopa with the denervated basal
ganglia is quite different depending on disease progression
at the time of treatment. These ﬁndings support both pre-
vious experimental work (Francardo et al., 2011; Lundbladet al., 2004; Winkler et al., 2002) and clinical observations
(Cilia et al., 2014).
To establish the MitoPark mouse as a preclinical animal
model to study the mechanisms and neuronal adaptations
occurring in the basal ganglia in response to DA replacement
therapy, and that eventually lead to the formation of LIDs, it
is important to ﬁrst demonstrate that this model recapitu-
lates some of the events associated with dyskinesias in
humans. The MitoPark genotype results in progressive loss
of DA afferents that spans several months. Starting at 12
weeks of age MitoPark mice show decreased locomotion in
the open ﬁeld. By 20 weeks of age, they have lost 60–70% of
their DA neurons in the SN and the decline in locomotor
activity is substantial (Ekstrand et al., 2007; Galter et al., 2010;
Good et al., 2011). As in humans suffering from Parkinson’s
disease, this motoric decline can be reversed by treatment
with the DA precursor L-Dopa (Ekstrand et al., 2007; Ekstrand
and Galter, 2009; Galter et al., 2010). From this point on, motor
deﬁcits progress, along with loss of ﬁne motor skills. This
eventually prevents MitoPark mice from eating and grooming
properly, and leads to a decline in their quality of life
reminiscent of the situation for Parkinson’s disease patients
Fig. 3 – Acute (A) and chronic (B and C) L-Dopa induced
locomotor behavior in 28-week old MitoPark and control
mice. Horizontal locomotor activity is plotted in 10 min
increments. L-Dopa injections were given after 60 min of
baseline recordings, and recordings continued for 2
additional hours (grey box). MitoPark and control mice
received the initial L-Dopa injection at 28 weeks of age (A),
and continued to receive daily L-Dopa injections for 2 weeks
until 30-weeks of age (C). Control mice did not develop
sensitization to L-Dopa treatment (white bars). Twenty
eight-week old MitoPark mice developed a rapid
sensitization to L-Dopa treatment (dark bars). After 2 weeks
of chronic L-Dopa treatment ((C) 30 weeks old), MitoPark
mice showed a signiﬁcantly faster onset to L-Dopa
treatment, as compared to the same cohort of mice after the
ﬁrst day of treatment (A). In addition, expression of
sensitization as related to chronicity of L-Dopa treatment
was more rapid and pronounced (both in onset and
duration) in MitoPark mice starting L-Dopa treatment at 28
weeks of age as compared to MitoPark mice starting
treatment at 20 weeks of age (Fig. 2).
Fig. 4 – Development of L-Dopa induced abnormal
involuntary movements over time in 20 and 28-week old
MitoPark mice after treatment with chronic daily L-Dopa
injections (10 mg/kg). All 28-week old MitoPark mice
showed abrupt and severe dyskinesias after the ﬁrst L-Dopa
injection. Twenty week old MitoPark mice did not develop
such severe dyskinetic movements until after 4–5 weeks of
chronic L-Dopa treatment. These data suggest that priming
for L-Dopa induced dyskinesia is signiﬁcantly accelerated in
MitoPark mice with severe DA depletion.
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2007). By 33 weeks of age MitoPark mice have lost 70–80% of
the nigral DA neurons, and present advanced parkinsonian
symptoms (Ekstrand et al., 2007; Ekstrand and Galter, 2009;
Galter et al., 2010). Also, as shown here by PCR arrays, the
state of neurotransmitter dynamics in the striatum of 28
week old MitoPark mice has fundamentally changed. Severe
loss of DA afferents in striatum of 28-week old MitoPark mice
causes signiﬁcant changes in the mRNA expression patternfor DA, GABA, glutamatergic, serotonergic and cholinergic
receptors. We therefore hypothesized that L-Dopa induced
dyskinesia would be signiﬁcantly accelerated in MitoPark
animals with advanced DA degeneration (28-week old), as
compared to animals with less advanced DA loss (20-week
old). Interestingly, the duration and peak response to acute L-
Dopa treatment was signiﬁcantly enhanced in MitoPark mice
with severe DA depletion, suggesting that older MitoPark
mice with more advanced Parkinson’s disease symptoms
sensitize more rapidly to DA replacement therapy. These
data correlated well with the development of LIDs. While all
28-week MitoPark mice showed severe dyskinesias after the
ﬁrst L-Dopa injection, 20-week old MitoPark mice did not
develop such severe dyskinetic movements until 4–5 weeks
after chronic L-Dopa treatment.
Recent literature underscores the relevance of the PCR
array data, reported here, that DA degeneration modiﬁed the
expression of a multitude of neurotransmitter receptors in
28-week old MitoPark mice, as compared to controls. For
example, 28-week old MitoPark mice showed a signiﬁcant
dysregulation of many glutamatergic receptor units (of 19
investigated levels of glutamate receptor mRNA species, 8
were signiﬁcantly decreased, while 3 were signiﬁcantly
increased). Recent studies have shown the value of NMDA
receptor blockade in humans to treat the development of
LIDs. A study in advanced Parkinson’s disease patients
showed that amantadine reduced dyskinesia severity and
improved motor ﬂuctuations in L-Dopa treated individuals
(Verhagen et al., 1998). Furthermore, a Phase IIb study
showed that patients with moderate to severe Parkinson’s
disease showed signiﬁcant improvement in dyskinesia sever-
ity after treatment with AFQ056, a potent selective mGluR5
inhibitor (Stocchi et al., 2013). We also found signiﬁcant
changes in mRNA expression for cholinergic receptors in
striatum of 28-week old MitoPark mice. A study using Pitx-3
deﬁcient aphakia mice has shown that chronic L-Dopa
induces ERK activation in striatal cholinergic interneurons,
Table 1 – Dysregulation of neurotransmitter receptor genesin striatum of 28-week old MitoPark mice as compared to age-
matched controls. Marked alterations are shown in bold.
GeneBank Symbol Description Fold change p value
NM_013461 Adra1a Adrenergic receptor, alpha 1a 1.2713 0.01034
NM_013460 Adra1d Adrenergic receptor, alpha 1d 1.6758 0.334303
NM_007417 Adra2a Adrenergic receptor, alpha 2a 1.6216 0.033766
NM_007420 Adrb2 Adrenergic receptor, beta 2 1.3255 0.00113
NM_013462 Adrb3 Adrenergic receptor, beta 3 1.3003 0.256787
NM_016847 Avpr1a Arginine vasopressin receptor 1A 2.1497 0.009146
NM_011924 Avpr1b Arginine vasopressin receptor 1B 1.0206 0.670543
NM_009766 Brs3 Bombesin-like receptor 3 1.6186 0.125584
NM_007627 Cckbr Cholecystokinin B receptor 1.1834 0.208665
NM_007698 Chrm1 Cholinergic receptor, muscarinic 1, CNS 0.8805 0.101805
NM_007699 Chrm4 Cholinergic receptor, muscarinic 4 0.7734 0.003584
NM_205783 Chrm5 Cholinergic receptor, muscarinic 5 1.685 0.040201
NM_145129 Chrna3 Cholinergic receptor, nicotinic, alpha polypeptide 3 0.8013 0.124339
NM_015730 Chrna4 Cholinergic receptor, nicotinic, alpha polypeptide 4 1.3541 0.220213
NM_176844 Chrna5 Cholinergic receptor, nicotinic, alpha polypeptide 5 0.9552 0.783436
NM_021369 Chrna6 Cholinergic receptor, nicotinic, alpha polypeptide 6 1.0048 0.943585
NM_007390 Chrna7 Cholinergic receptor, nicotinic, alpha polypeptide 7 0.8026 0.011896
NM_009603 Chrne Cholinergic receptor, nicotinic, epsilon polypeptide 1.0776 0.186884
NM_007726 Cnr1 Cannabinoid receptor 1 (brain) 0.6518 0.007608
NM_010076 Drd1a Dopamine receptor D1A 0.7846 0.017427
NM_010077 Drd2 Dopamine receptor D2 0.9356 0.497982
NM_013503 Drd5 Dopamine receptor D5 1.4165 0.00071
NM_019439 Gabbr1 (GABA) B receptor, 1 0.9429 0.135509
NM_001081141 Gabbr2 (GABA) B receptor, 2 1.163 0.145911
NM_010250 Gabra1 (GABA) A receptor, subunit alpha 1 1.2985 0.07144
NM_008066 Gabra2 (GABA) A receptor, subunit alpha 2 1.3524 0.071727
NM_010251 Gabra4 (GABA) A receptor, subunit alpha 4 0.8071 0.003188
NM_176942 Gabra5 (GABA) A receptor, subunit alpha 5 1.2922 0.011022
NM_008068 Gabra6 (GABA) A receptor, subunit alpha 6 1.0883 0.586606
NM_008069 Gabrb1 (GABA) A receptor, subunit beta 1 1.0397 0.400714
NM_008071 Gabrb3 (GABA) A receptor, subunit beta 3 0.8539 0.051473
NM_008072 Gabrd (GABA) A receptor, subunit delta 0.7827 0.007242
NM_017369 Gabre (GABA) A receptor, subunit epsilon 1.385 0.135854
NM_010252 Gabrg1 (GABA) A receptor, subunit gamma 1 1.2759 0.03047
NM_008073 Gabrg2 (GABA) A receptor, subunit gamma 2 1.0238 0.710742
NM_008074 Gabrg3 (GABA) A receptor, subunit gamma 3 0.8601 0.144219
NM_020488 Gabrq (GABA) A receptor, subunit theta 1.2317 0.281796
NM_008075 Gabrr1 (GABA) C receptor, subunit rho 1 1.3599 0.021585
NM_008076 Gabrr2 (GABA) C receptor, subunit rho 2 1.9866 0.001767
NM_008101 Gcgr Glucagon receptor 1.0847 0.603755
NM_008165 Gria1 Glutamate receptor, ionotropic, AMPA1 1.1595 0.001987
NM_013540 Gria2 Glutamate receptor, ionotropic, AMPA2 0.8209 0.014424
NM_016886 Gria3 Glutamate receptor, ionotropic, AMPA3 0.9255 0.330373
NM_146072 Grik1 Glutamate receptor, ionotropic, kainate 1 1.6701 0.047624
NM_010349 Grik2 Glutamate receptor, ionotropic, kainate 2 0.8522 0.005992
NM_175481 Grik4 Glutamate receptor, ionotropic, kainate 4 1.5347 0.000566
NM_008168 Grik5 Glutamate receptor, ionotropic, kainate 5 0.7479 0.01214
NM_008169 Grin1 Glutamate receptor, ionotropic, NMDA1 0.8635 0.017452
NM_008170 Grin2a Glutamate receptor, ionotropic, NMDA2A 0.8861 0.074721
NM_008171 Grin2b Glutamate receptor, ionotropic, NMDA2B 0.8552 0.014799
NM_010350 Grin2c Glutamate receptor, ionotropic, NMDA2C 0.907 0.258151
NM_016976 Grm1 Glutamate receptor, metabotropic 1 0.9209 0.022333
NM_181850 Grm3 Glutamate receptor, metabotropic 3 0.8678 0.020762
NM_001013385 Grm4 Glutamate receptor, metabotropic 4 0.882 0.109941
NM_001081414 Grm5 Glutamate receptor, metabotropic 5 0.7745 0.004797
NM_173372 Grm6 Glutamate receptor, metabotropic 6 1.0388 0.980826
NM_177328 Grm7 Glutamate receptor, metabotropic 7 1.0267 0.690845
NM_008174 Grm8 Glutamate receptor, metabotropic 8 1.0772 0.371807
NM_008177 Grpr Gastrin releasing peptide receptor 1.3413 0.198779
NM_198962 Hcrtr2 Hypocretin (orexin) receptor 2 1.5415 0.018631
NM_008285 Hrh1 Histamine receptor H1 1.219 0.193255
NM_153087 Hrh4 Histamine receptor H4 1.1032 0.369374
NM_008308 Htr1a Sertonin receptor 1A 1.6091 0.007967
NM_010482 Htr1b Serotonin receptor 1B 1.0809 0.385587
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Table 1 (continued )
GeneBank Symbol Description Fold change p value
NM_008309 Htr1d Serotonin receptor 1D 0.9676 0.670621
NM_008310 Htr1f Serotonin receptor 1F 0.9772 0.654426
NM_172812 Htr2a Serotonin receptor 2A 1.3284 0.032927
NM_008311 Htr2b Serotonin receptor 2B 1.1198 0.001279
NM_008312 Htr2c Serotonin receptor 2C 1.3043 0.05377
NM_013561 Htr3a Serotonin receptor 3A 1.2509 0.044708
NM_008313 Htr4 Serotonin receptor 4 1.1655 0.003944
NM_008315 Htr7 Serotonin receptor 7 1.7551 0.048707
NM_008731 Npy2r Neuropeptide Y receptor Y2 1.561 0.003761
NM_016708 Npy5r Neuropeptide Y receptor Y5 0.9597 0.502927
NM_008747 Ntsr2 Neurotensin receptor 2 1.2378 0.02537
NM_001081147 Oxtr Oxytocin receptor 1.5892 0.068579
NM_144944 Prokr2 Prokineticin receptor 2 1.0258 0.854078
NM_009216 Sstr1 Somatostatin receptor 1 1.1627 0.354588
NM_009217 Sstr2 Somatostatin receptor 2 1.4627 0.00043
NM_009219 Sstr4 Somatostatin receptor 4 1.123 0.088049
NM_009313 Tacr1 Tachykinin receptor 1 1.0869 0.235536
NM_009314 Tacr2 Tachykinin receptor 2 0.7827 0.125587
NM_021382 Tacr3 Tachykinin receptor 3 1.0642 0.435184
NM_009775 Tspo Translocator protein 1.4052 0.031808
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expression of LIDs (Ding et al. 2011). As cholinergic tone
contributes to DA and glutamate release locally via presy-
naptic nicotinic receptors on DA and glutamatergic terminals,
our data suggest changes in cholinergic neurotransmission
may be involved in the development of motor complications.
It will be important to dissect which of the neurotransmitter
changes observed in this study contribute to the antiparkin-
sonian effects associated with L-Dopa treatment, and/or to
the development of dyskinesias.
We used HPLC measurement of DA and DOPAC to docu-
ment the age related loss of dopaminergic projection in these
mice. We did not carry out a more extensive characterization
because, with respect to the nigrostriatal DA system, of
previously published immunohistochemical studies, bio-
chemical studies, cell counts, pharmacological studies and
electrophysiological studies documenting the neurodegen-
erative events in MitoPark mice (Ekstrand et al. 2007; Galter
et al. 2010; Gellhaar et al., 2015; Good et al. 2011). The genetic
nature of the model, leading to identical progressive loss of
the DA system with time in all MitoPark mice, shows a
correlation between the response to L-Dopa and the degree
of degeneration, based on the age-related changes in the
MitoPark DA system which are extensively documented in
the studies cited above.
To conclude, we show that MitoPark mice develop a
differential type of response to L-Dopa treatment depending
on the extent of DA neurodegeneration. The MitoPark mouse
model offers an opportunity to study plastic rearrangements
occurring in the basal ganglia during slowly progressive DA
loss, and the potential impact of therapeutic interventions
when animals are suffering from mild, moderate or severe
Parkinson’s disease symptoms. This may help progress
towards the goal of improving the effectiveness of L-Dopa
replacement therapies, while avoiding or inhibiting the
development of L-Dopa induced dyskinesias. Moreover, ourdata strongly supports the view that delaying the initiation of
L-Dopa treatment does not delay the development of LIDs.4. Experimental procedure
4.1. Animals
All animal studies were conducted under National Institutes
Health (NIH) Guidelines using the NIH handbook Animals in
Research and were approved by the Institutional Animal Care
and Use Committee (National Institute on Drug Abuse,
Intramural Research Program, Baltimore, MD). The TfamloxP
(Ekstrand et al., 2007) line was mixed with the Slc6a3Cre
(Backman et al., 2006) to obtain regional knockout (Slc6a3Cre/
wtTfamloxP/loxP, or MitoPark) and control mice (Slc6a3Cre/wt
Tfamwt/wt, or WT). Animals were genotyped using TfamloxP
and Slc6a3Cre primers as described elsewhere (Backman et al.,
2006; Ekstrand et al., 2007). Animals received pelleted food
and water ad libitum. From 20 weeks of age, ground mouse
chow was also supplied. Mice were sacriﬁced using CO2
inhalation at the end of the experimental procedures and
tissue samples were collected after death was veriﬁed.4.2. HPLC analyses of DA and metabolites
Striatal tissue from 20 and 28 week old WT and MitoPark mice
(n¼5) for each genotype and age group) were dissected,
weighed and stored at 80 1C until extraction. Tissue sam-
ples were homogenized in 0.1 M perchloric acid and centri-
fuged at 25,000g for 12 min. DOPAC, DA, and HVA in
supernatants were measured by HPLC with electrochemical
detection (Waters 717 Plus automated injection system;
Waters 1525 Binary pump; ESA Coulochem III detector). The
column (Waters SunFire C18 5 mm; 4.6150.0 mm) received a
mobile phase (0.01 M sodium dihydrogenphosphate, 0.01 M
b r a i n r e s e a r c h 1 6 1 8 ( 2 0 1 5 ) 2 6 1 – 2 6 9268citric acid, 1.2 mM sodium EDTA, 1.2 mM sodium 1-heptane
sulfonic acid, 10% methanol, pH 3.5) at ﬂow rate 1.0 ml/min
and a column temperature of 34 1C. Concentrations of
DOPAC, DA and HVA were calculated as pg/mg of tissue
weight. Statistical analysis was performed using analysis of
variance (ANOVA) followed by Fisher’s protected least sig-
niﬁcant difference (PLSD) (StatView 4.02,SAS Institute, Cary,
NC). Criteria for signiﬁcance were set at po0.05 (npo0.05,
nnpo0.01, nnnpo0.001).
4.3. RT2 proﬁler neurotransmitter receptors arrays
To determine how DA denervation affected the pattern of
mRNA expression for various neurotransmitter receptors in
striatum, PCR microarrays for 84 mRNA species involved in
neurotransmission were used. Striatal tissue was dissected from
28-week old naïve WT (n¼6) and Mitopark mice (n¼6) and was
immediately processed for total RNA isolation and DNAse I
treatment (RNAqueous-Micro Ambion kit, Applied Biosystems
Ambion, Austin, TX), following the manufacturer’s instructions.
Total RNA from individual animals were reverse-transcribed
into cDNA (RT2 First strand Kit, SABiosciences, mixed with a
qPCR mastermix containing SYBR Green, SA Biosciences), and
aliquoted in equal volumes to each well of the PCR microarrays
(Mouse synaptic plasticity RT2 Proﬁler™PAMM-060Z, SA Bios-
ciences). A separate array was used for each animal. After real-
time PCR (HT7900 Cycler, Applied Biosystems), data were
normalized using appropriate software (http://pcrdataanalysis.
sabiosciences.com/pcr/arrayanalysis.php).
4.4. Treatment regimen
L-Dopa, and benserazide hydrochloride (Sigma-Aldrich, St.
Louis, MO) were dissolved in 0.9% saline. L-Dopa (10 mg/kg)
was injected i.p. together with benserazide (5 mg/kg) to inhibit
peripheral dopa decarboxylase. L-Dopa was injected twice a
day (morning and late afternoon), except for weekends, when
injections were given only in the morning. Daily L-Dopa
treatment was initiated in two different cohorts of MitoPark
mice and age-matched controls (n¼8 in each group) at 20
weeks of age (moderate DA loss), and 28 weeks of age (marked
DA loss), respectively. 20-week old mice were treated with L-
Dopa for a period of 10 weeks, until they were 30 weeks old.
28-week old mice were treated with L-Dopa for a period of 2
weeks, also until they were 30 weeks old. Behavioral analyses
were performed weekly after initiation of L-Dopa treatment.
4.5. Locomotor behavior
Locomotor activity was recorded using activity chambers placed
into analyzers, where activity was monitored through a grid of
infrared light beams (Versamax, Accuscan instruments). Control
and MitoPark mice were habituated (day 0) to the chambers and
to the injection protocol prior to L-Dopa treatment. On day 0,
control and Mitopark mice were placed in the locomotor activity
chambers for a 1-h habituation period. Thereafter, animals
received an i.p. saline injection and were placed back into the
chamber for two additional hours. Behavioral recordings started
at 20 weeks of age (moderate DA degeneration), or 28 weeks of
age (severe dopamine degeneration) and continued every week,until the end point of the study at 30 weeks of age. There were 8
animals in each of the four treatment groups. We chose to use
20 weeks as an initial age since there is a robust PD-like
phenotype, as oppose to smaller changes in behavior and
dopamine dynamics at younger MitoPark ages. Recording ses-
sions lasted 180min. All behavioral tests were done between
9:00 am and 1:00 pm. Data are presented as the mean and
standard error of the mean. Two-way analysis of variance with
Bonferroni post hoc comparisons for multiple measurements
was performed. A p value of o0.05 was considered signiﬁcant
(npo0.05, nnpo0.01, nnnpo0.001).
4.6. Quantiﬁcation of L-Dopa induced dyskinesia
Animals were placed in a small transparent cylinder 60min
after treatment initiation with L-Dopa, as it coincided with
maximal horizontal activity in 20-week old Mitopark mice, and
was continued each week thereafter. Spontaneous activity was
videotaped for 3min and the middle 2min were analyzed
manually to quantify dyskinesias and L-Dopa induced motor
abnormalities. Abnormal paw movements exhibited in the
cylinder were scored as previously described (Ding et al., 2007).
Front paw dyskinesia was noted when mice stood on both hind
paws, with both front paws moving repeatedly up and down
along the surface of the cylinder wall. Hind paw touch was
noted when mice stood on their hind paws and repeatedly
touched the surface of the cylinder wall with one hind paw.
Three paw dyskinesia was noted whenmice stood on their hind
paws close to the wall of the cylinder moving both front paws as
noted above and repeatedly lifting the hind paws up and down
in an alternating fashion while maintaining their weight on the
other hind paw. A few MitoPark mice developed an abnormal
rotational response to L-Dopa treatment, which increased over
treatment time. This type of L-Dopa-induced uninterrupted
rotational behavioral response was considered a motor compli-
cation induced by L-Dopa treatment. The sum of hind paw, three
paw dyskinesia and abnormal rotational behavior were used to
score total abnormal involuntary movements or L-Dopa induced
dyskinesias (LIDs). Data are presented as themean and standard
error of themean. Two-way analysis of variance with Bonferroni
post hoc comparison was performed (measured points in both
20- and 28-week old groups, were compared to abnormal
involuntary movements in 20-week old Mitopark mice chroni-
cally treated with L-Dopa for 1 week; see Fig. 4). A p value of
o0.05 was considered signiﬁcant (npo0.05, nnpo0.01,
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